PM Tracker

After bringing on a new global chief marketing officer, Pfizer is now moving former oncology president Andy Schmeltz to a new role focused on business development, with rare disease president Suneet Varma taking his place.

In two separate cases settled this week, Philips will pay the U.S. Department of Justice a total of about $29 million, resolving allegations of wrongdoing in its medical device sales.

Boehringer Ingelheim gained an FDA approval to treat generalized pustular psoriasis, a rare and life-threatening skin condition that causes eruptions of painful blisters. Spevigo is an IL-36 receptor inhibitor, and marks the first dermatology go-ahead for the German firm.

Many companies have adopted an in-licensing business model to bring drugs by Western biotechs to China. But Sanofi veteran Joanne Jiang, Ph.D., believes her new company, LeaderMed, has a unique business proposition to tackle China’s metabolic disease market and could attract U.S. investors in a New York IPO.

Walgreens Boots Alliance finalized its majority stake investment in CareCentrix as competition in the home health space heats up.

The FDA trimmed its authorizations for Lilly and Regeneron’s antibodies early in the year on data that suggested they weren’t effective against the omicron variant. Despite the FDA ban, however, hospitals and health systems administered more than 158,000 deauthorized monoclonal antibody doses in early 2022, a new JAMA study contends.

Insurer groups are clamoring that CMS scrap a controversial proposed rule that could leave plans on the hook for greater overpayments to Medicare.

Precision BioSciences is rejigging its senior leadership team, putting Jeff Smith, Ph.D., in charge of its research programs and asking Chief Scientific Officer Derek Jantz, Ph.D., to focus on “formulating company strategy and managing relationships with external stakeholders.”

A new artificial intelligence model developed by researchers at the Mayo Clinic is aiming to chart a clear path through the maze of possible complications that can crop up throughout the labor and delivery process.

Learn how a private health insurance company uses analytics to deliver exceptional service to its employees and members

Today’s healthcare systems are adapting to an ever changing landscape with declining margins, M&A pressures, and the need for staff flexibility due to shortages. Read our whitepaper and dive into the way healthcare providers can digitally transform day-to-day work by streamlining costs and increasing agility by removing manual paper burdens.

This paper explores how Medical Affairs is increasingly playing a key leadership role in evidence planning and generation (part 3 in a series).

How can we predict the ability of a preclinical drug to inadvertently cause or intentionally inhibit cytokine secretion and T cell activation

Improve your congress competitive intelligence and cut down costs by 50%

Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success.

Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals.

Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella.

Set a solid foundation for successful scale-up of buffer preparation.

The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services.

See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead.

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?

Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry.

Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays?

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.